Collaborative Cancer Survivorship Research Centre 2021


As highlighted in the National Cancer Strategy 2017-2026, advances in cancer treatment are greatly increasing survival rates for patients, with approximately 200,000 people in Ireland now living with and beyond cancer. However, the consequences of cancer and its treatment can result in significant, often lifelong, effects on health and quality of life.

The Irish Cancer Society is dedicated to improving the experiences, quality of life, and outcomes of all those living with and beyond cancer. In recognition of this commitment, outlined in the Society Strategy 2020-2025 and Research Roadmap, the Irish Cancer Society has invested significantly into identifying and addressing the survivorship needs of people with cancer.  

To date, the Society has made focused investments into capacity-building career awards (e.g. Scholarships, Fellowships, and Cancer Nursing Research Awards) and specific purpose project grants (e.g. Women’s Health Initiative). While these investments have provided important and impactful opportunities to advance research in specific areas, it is now time to unite our efforts into a national cancer research collaboration.

The Irish Cancer Society has had previous success with such endeavours in the biomedical sciences, for instance, BREAST-PREDICT and Blood Cancer Network Ireland (BCNI). These programmes fostered collaboration between institutions and disciplines, facilitating research excellence, opportunity for career progression, and the retention of cancer research expertise in Ireland.

It is now time to apply this format of national cooperation to cancer survivorship by establishing a Collaborative Cancer Survivorship Research Centre. 

Please see the Guidelines for Applicants for more information


Funding of €4,000,000 (€800,000 per annum) is available for a core award to drive forward a programme of up to 5 years in duration. Funding is available to cover the following costs: salary (including PhD studentships, Post-Doctoral fellowships, and clinical buy-out time), consumables, equipment, education/training, dissemination, and patient and stakeholder involvement. Only direct costs are payable and, as such, overheads/indirect costs are not eligible.

It is explicitly anticipated that the successful application will utilise the core funding from the Society to leverage significant financial and other co-investment in the programme from other stakeholders, institutions, companies, philanthropy, etc. Proposals that make maximum financial leverage of a core investment by the Society will get a more favourable weighting in the review process.

How to apply

Applications will open 08 December 2021. Applications must be completed and submitted through the Irish Cancer Society Gateway Grant Tracker online system. In order to submit an online application, you are required to register at the following address:

Deadline for applications: 3:00pm, Wednesday, 15 February 2022 

8 DecemberEOI applications open
15 February 2022, 3.00pm EOI application deadline
Early April 2022EOI outcome announced and Full Applications open to shortlisted applications
5 July 2022, 3.00pmFull applications close
End September 2022Interviews
Q1 2023Programme start

*Dates are subject to change at the discretion of the Society.

Guidelines and documents
Documents to download